Is Liver Cancer Curable? Things to Know

It’s not easy when you’re the receiving end of a diagnosis of liver cancer. Your emotions will be on a rollercoaster motion not knowing what to do. However, it’s important to keep things together so you can have better health outcomes. So, is liver cancer curable? Let’s find out.

Liver cancer affects more than 42,000 Americans on a yearly basis. It has varying curability rates depending on the stage and treatment approach. Early detection can lead to curative regimens through surgery or transplant. But treatment for advanced stages aims at managing the symptoms and extending life as comfortably as it could. The advances in treatment like immunotherapy and targeted treatments offer new hope for patients. Patients with liver cancer in stages I-II (early stages) have five-year survival rates that reach up to 60-70%.

Key Insights:

• Early-stage liver cancer (stages I-II) offers the best chance for cure with surgery or transplant, achieving 5-year survival rates of 60-70%

• Hepatocellular carcinoma (HCC) represents over 90% of all liver cancer cases, often linked to hepatitis B/C infections

• Prevention through hepatitis B vaccination can reduce liver cancer risk by up to 72% for virus-related cases

• Regular screening for high-risk groups significantly improves outcomes and treatment options

• New treatments like immunotherapy and AI-assisted diagnostics are changing survival rates at major medical centers

What Are the Types of Liver Cancer?

The main types of liver cancer are hepatocellular carcinoma (HCC), the most common, and intrahepatic cholangiocarcinoma (ICC). Others include fibrolamellar HCC and angiosarcomas. These differences help doctors choose the right treatment approach and give patients realistic expectations about their health challenges and outcomes.

HCC accounts for roughly more than 90% of all liver cancer cases in the United States. This type develops in the main liver cells and often occurs in people with chronic liver disease or cirrhosis. HCC rates have been climbing steadily due to increasing hepatitis C infections and fatty liver disease.

ICC represents about 10-15% of liver cancers. It starts in the bile ducts within the liver. This type tends to be more aggressive than HCC and often has different risk factors, including primary sclerosing cholangitis and certain parasitic infections more common in other parts of the world.

Other rare forms include:

• Fibrolamellar HCC–typically affecting younger people without cirrhosis

• Angiosarcoma–develops in the blood vessels in the liver

• Hepatoblastoma–primarily affects children under the age of 3

What Is Hepatocellular Carcinoma (HCC)?

HCC is liver cancer that starts in hepatocytes, the main liver cells. Most cases develop in people who already have liver damage from long-term conditions like cirrhosis or chronic hepatitis infections.

The risk factors include:

• Chronic hepatitis B or C infection

• Cirrhosis from any cause

• Excessive alcohol use

• Metabolic associated steatohepatitis (MASH), formerly known as NASH (non-alcoholic steatohepatitis)

People who are at risk for developing liver cancer need regular screening every 6 months with ultrasound and alpha-fetoprotein (AFP) blood tests. When liver cancer is early detected, it dramatically improves treatment response and survival rates.

Recommended screening is recommended for the following population:

• Anyone with cirrhosis regardless of the cause

• Adults with chronic hepatitis B or C infection

• People diagnosed with MASH or advanced liver cirrhosis

Cirrhosis is associated with HCC. They are positively correlated with an incidence of 2-3% HCC in people with cirrhosis each year. This makes monitoring and screening essential for anyone with known liver scarring.

What Is Intrahepatic Cholangiocarcinoma (ICC)?

ICC is a bile duct cancer within the liver. It is different from HCC in symptoms and treatment response. It tends to have lower survival rates and different risk factors like primary sclerosing cholangitis. Unlike HCC, ICC often develops without underlying liver cirrhosis, which makes it harder to predict and screen for. This type affects the bile ducts inside the liver, which carry bile from liver cells to the gallbladder and intestines. ICC has been shown to increase in incidence over the past years but it has remained relatively uncommon compared to HCC.

Key differences from HCC include:

• It often occurs without any underlying liver disease or cirrhosis

• More likely to cause bile duct obstruction and jaundice early in the disease

• Generally has poorer prognosis than HCC

• Less responsive to liver transplantation

• Different biomarker patterns on blood tests

Risk factors attributed to ICC include inflammatory bowel disease, liver fluke infections (although rare in the US), and certain genetic conditions that affect bile duct development.

What Causes Liver Cancer?

Liver cancer is often caused by chronic liver damage from hepatitis B or C, cirrhosis, or fatty liver disease. Other factors include obesity, diabetes, and aflatoxin exposure. The common thread is long-term inflammation that damages liver cells and increases cancer risk over time.

Most liver cancers develop after years of chronic inflammation. The liver tries to repair itself repeatedly, but this process can go wrong and lead to cancerous changes. Understanding these causes helps people take steps to protect their liver health.

Major risk factors in the United States include:

• Chronic hepatitis B or C infection (leading cause worldwide)

• Cirrhosis from alcohol use disorder

• Metabolic associated steatohepatitis (MASH)

• Type 2 diabetes and obesity

• Exposure to aflatoxins from moldy grains or nuts

• Certain genetic disorders like hemochromatosis

It has been emphasized that many of these risk factors are preventable through lifestyle changes, vaccinations, and proper management for existing chronic conditions.

What Role Does Hepatitis Play in Liver Cancer?

Hepatitis B and C are top causes of liver cancer with vaccination and treatment preventing most cases. Hepatitis B vaccine can reduce the risk by up to 72% when properly administered. Chronic infection with either hepatitis B or C virus can cause continuous inflammation that can lead to cirrhosis and eventually cancer.

The Hepatitis B vaccine has dramatically reduced the rate of liver cancer in many countries with widespread immunization. In the US, most new hepatitis B infections occur in unvaccinated adults, making catch-up vaccination important for high-risk groups.

For hepatitis C, new direct-acting antiviral (DAA) treatments can bring cure for more than 95% of cases. People who managed to clear their infection have significantly lower risk of developing liver cancer. But some risk is retained if cirrhosis has already set in.

Screening recommendations include:

• All adults should be tested for hepatitis B and C at least once

• People born between 1945-1965 need hepatitis C testing

• Regular monitoring for those with chronic infections

• Immediate family members of infected individuals should be tested

The combination of vaccination, treatment, and screening could prevent most hepatitis-related liver cancers.

How Does Cirrhosis Contribute to Liver Cancer?

Cirrhosis increases your risk of developing liver cancer. And, it has been shown that up to 90% of patients with liver cancer have cirrhosis. Any cause of cirrhosis increases the risk, whether it is from alcohol, hepatitis, or metabolic disease. The scarred liver struggles to function normally and becomes more prone to developing cancerous changes.

Alcoholic cirrhosis and cirrhosis from MASH are becoming more common causes of liver cancer in the US. It has been shown that MASH is the fastest-growing cause of liver transplant needs in America.

The progression typically follows this pattern:

• Chronic liver damage from various causes

• Development of fibrosis (early scarring)

• Progression to cirrhosis (advanced scarring)

• Increased cancer risk requiring regular monitoring

People with cirrhosis need ultrasound screening every six months. This is because early detection can significantly improve treatment success and outcome. Even with cirrhosis, a lot of treatment options today remain available when cancer is caught early.

What Are the Symptoms of Liver Cancer?

Early symptoms may be absent, but later include jaundice, abdominal pain, weight loss, and fatigue. Seek medical help if these symptoms persist or worsen. Many people don’t notice the symptoms until the cancer has grown larger or spread, which is why screening matters so much for high-risk individuals.

Liver cancer symptoms often overlap with those of chronic liver disease, which makes the diagnosis very challenging. 

Liver cancer symptoms often overlap with those of chronic liver disease, making diagnosis challenging. The liver's remarkable ability to function even when significantly damaged means symptoms may not appear until cancer is advanced.

When symptoms occur, they may be vague and unspecific, including:

• Unexplained weight loss over several weeks

• Loss of appetite or feeling full faster than usual

• Upper right abdominal pain or discomfort

• Swelling in the abdomen (ascites)

• Yellowish discoloration of the skin and eyes (jaundice)

• Unusual fatigue or weakness not relieved by rest

• Nausea

• Vomiting

The basic premise is to recognize these symptoms, which represent a sudden shift in baseline, especially for people who are known to have liver disease.

What Are Early Signs of Liver Cancer?

There is not much difference between early signs of liver cancer and when it is finally diagnosed. But the difference could lie on the duration, onset, and severity of these signs that may easily be ignored or mistaken for some minor illness.

Subtle signs would include unintentional weight loss, loss of appetite, or mild abdominal discomfort that may just go away on its own. If you are among the high-risk individuals, you should watch for any changes in symptoms or your usual symptoms.

But you need to understand that early stages of liver cancer rarely cause obvious symptoms, which is why medical monitoring is essential for people with chronic liver conditions.

Some of these early signs include the following:

• Weight loss of 10 pounds or more without trying or without intention

• Persistent loss of appetite

• New or worsening abdominal pain, localized or around the upper right abdominal area

• Feeling unusually tired despite getting adequate rest or sleep

• Mild nausea that does not improve

People with existing liver disease should report any symptom changes to their healthcare team promptly. What seems like a minor change can be your sign for cancer development.

What Are Advanced Symptoms of Liver Cancer?

Severe signs include ascites (fluid buildup), internal bleeding, and worsening jaundice compared to earlier stages. These symptoms indicate more advanced cancer, which requires immediate medical attention. Advanced liver cancer can cause serious complications that may need emergency treatment.

Advanced symptoms of liver cancer may include:

• Significant abdominal swelling from fluid accumulation

• Severe yellowing of the skin and whites of the eyes

• Dark urine and pale-colored stools

• Easy bruising or bleeding

• Confusion or changes in mental status or function

• Severe fatigue that will interfere with daily activities

These symptoms often indicate that the cancer has grown large or affected liver function significantly. While advanced symptoms are serious, there are still treatments that are available to help manage the disease and maintain quality of life.

How Is Liver Cancer Diagnosed?

Diagnosis for liver cancer involves imaging like computed tomography (CT) and magnetic resonance imaging (MRI), blood tests like AFP, and sometimes when confirmatory testing is required, biopsy.

High-risk individuals need to be monitored every 6 months. The diagnostic process is focused on finding cancer as early as possible when treatment options are most effective. The National Cancer Institute has established a step-by-step approach in the diagnosis, starting from blood tests and imaging. The process often takes several weeks to complete all necessary tests and determine the best treatment plan.

Standard diagnostic steps include:

• AFP (alpha-fetoprotein) blood test–elevated in many liver cancers

• Complete blood count

• Liver function tests

• Hepatitis B and C screening if not yet done previously

• Imaging tests beginning with an ultrasound

• Advanced imaging like CT or MRI for comprehensive images

• Possible biopsy, if physical exam, imaging results, and blood tests remain inconclusive

The costs of these tests and diagnostics vary considerably, but most insurance plans cover the necessary diagnostic testing for people with risk factors or symptoms. Early detection through screening costs a lot less than the treatment for advanced cancer.

What Imaging Tests Are Used for Liver Cancer?

Ultrasound, CT, and MRI each offer different advantages for detecting and staging liver cancer. Recent AI advancements help radiologists spot subtle or small tumors more accurately. The choice of imaging will depend on the specific situation and what information doctors need.

Comparison of imaging methods:

Research shows that combining different imaging techniques improves accuracy in diagnosing liver cancer. AI-assisted scans are becoming more common and help catch tumors that might be missed otherwise. Also, the timing of contrast injection during CT or MRI scans is crucial because liver tumors have characteristic enhancement patterns that help distinguish them from benign tumors.

When Is a Biopsy Needed for Liver Cancer?

Biopsy confirms diagnosis when imaging results are unclear or show unusual patterns. Before biopsy, all the risks and benefits will be weighed first. Many liver cancers can be diagnosed based on imaging alone, especially in people with known risk factors.

Biopsy may be needed when:

• Imaging shows a liver mass but enhancement patterns are atypical

• Multiple small nodules are present and diagnosis is uncertain

• Cancer type needs to be determined for treatment planning

• Clinical picture doesn't match imaging findings

The main risk of liver biopsy is bleeding, especially in people with cirrhosis or blood clotting problems. Newer techniques like core needle biopsy performed with CT guidance have reduced complication rates significantly. Most major medical centers use a multidisciplinary approach where radiologists, oncologists, and surgeons review all imaging together before deciding if biopsy is necessary.

What Are the Treatment Options for Liver Cancer?

The treatment includes surgery, transplant, ablation, embolization, radiation, targeted therapy, and immunotherapy. But it all depends on the stage and overall health. Success rates for these treatment modalities vary considerably based on when cancer is detected and treated. Research states that the treatment should be patient-dependent, meaning it is centered on the patient’s cancer stage, liver function, and patient preferences.

In order for you to understand your treatment options, you need to understand the stage-dependent treatment guideline, as well. Access to specialized treatment centers also makes a significant difference in outcomes, especially for complex cases requiring multiple treatment approaches.

Treatment categories include:

Curative Treatments (aimed to remove all cancer):

• Surgical resection

• Liver transplantation

• Ablation (heat or cold)

Palliative treatments (aimed at controlling disease):

• Embolization procedures (blocking the blood supply to the liver)

• Systemic therapies (medications that work throughout the body)

• Radiation therapy (focused energy beams)

• Supportive care (managing symptoms and side effects)

The choice for the treatment procedure entirely depends on the tumor size, number of tumors, liver function, and overall health status.

What Surgical Treatments Are Available for Liver Cancer?

Surgical resection and liver transplant offer the best chances for cure, with 5-year survival rates of 55-71%. Transplant may be an option when tumors are small but surgery isn’t possible because of poor liver function. When patients meet certain and specific criteria for surgery, success rates are affected significantly.

Liver resection involves removing a part of the liver containing cancer. It takes advantage of the liver’s capacity to regenerate, which makes the procedure possible in the first place. The liver does so even when big portions have been removed. The best candidates for liver resection include:

• Good liver function (minimal cirrhosis)

• Limited number of tumors

• No spread outside the liver (localized)

• Good overall health for major surgery

Liver transplantation replaces the entire diseased liver with a new one and offers an excellent outcome for selected patients. Milan criteria help determine eligibility:

• Single tumor up to 5 cm, or

• Up to 3 tumors, each smaller than 3 cm

• No blood vessel invasion

• No spread outside the liver

Transplant waiting times vary by blood type and geographic location. But living donor transplants can reduce wait times significantly.

What Are Non-Surgical Treatments for Liver Cancer?

Ablation, embolization, and systemic therapies provide options when surgery isn't possible. These treatments can be regional (focused on the liver) or systemic (affecting the whole body).

Ablation techniques destroy tumors using:

• Radiofrequency ablation - heat energy

• Microwave ablation - electromagnetic energy

• Cryoablation - extreme cold

• Irreversible electroporation - electrical pulses

Embolization procedures block blood supply to tumors:

• Transarterial chemoembolization (TACE): the combination of chemotherapy and arterial blocking

• Transarterial radioembolization (TARE): uses radioactive beads

• Bland embolization (blocks artery without chemotherapy)

Systemic therapies include targeted drugs and immunotherapy that work throughout the body to fight cancer cells while minimizing damage to healthy tissue.

What Is the Prognosis for Liver Cancer?

Prognosis varies considerably by stage, with early stage HCC having a 5-year survival rate of approximately 30-50% while advanced stages only have a 5-year survival rate of less than 12.5%. Curability improves dramatically with early detection and proper treatment. And, new therapies offer hope even for advanced cases, and survival statistics continue improving as treatments advance.

There is an encouraging trend in liver cancer survival, especially at specialized centers. Factors that improve prognosis include young age, good liver function, early stages at the time of diagnosis, and access to comprehensive care teams.

Recent advances contributing to better outcomes:

• Improved surgical techniques and patient selection

• New targeted therapies and immunotherapy drugs

• Better management of underlying liver disease

• Enhanced imaging for earlier detection

• Multidisciplinary care teams

Individual prognosis depends on many factors beyond just cancer stage, including overall health, response to treatment, and access to specialized care.

What Are Survival Rates by Stage for Liver Cancer?

Five-year survival rates by stage using SEER data show significant differences between early and advanced disease. Stage I patients have 40-60% five-year survival, while Stage IV drops to 5-10%. These statistics represent averages and individual outcomes may vary significantly based on specific circumstances.

Here’s a detailed breakdown of the 5-year survival rates:

• Stage I (single tumor, no spread): 60-80%

• Stage II (single tumor with blood vessel involvement): 30-50%

• Stage III (multiple tumors or nearby organ involvement): 15-30%

• Stage IV (distant spread): 5-10%

It's important to remember that these statistics reflect outcomes over the past several years and don't account for the newest treatments becoming available. Many patients fare better than other patients probably because they have access to better and specialized centers.

Nonetheless, you need to understand that survival depends also on the remaining liver function. Patients with better underlying liver health generally do better regardless of the stage.

What Factors Affect Liver Cancer Prognosis?

Age, overall health, tumor characteristics, and liver function all influence outcomes significantly. Lifestyle changes and proper medical care can improve prognosis even after diagnosis. Patients who maintain good diet and nutrition and regular exercise when possible tend to have better outcomes.

Key prognostic factors:

• Tumor factors (size, number, blood vessel invasion)

• Liver function (degree of cirrhosis, albumin levels, bilirubin)

• Patient factors (age, overall health, nutritional status)

• Treatment factors (access to specialized care, clinical trial participation)

Maintaining good nutrition, avoiding alcohol, managing diabetes, and staying as active as possible can all positively influence outcomes. Social support and mental health care also play important roles in helping patients cope with treatment and maintain quality of life.

Even patients with advanced disease can benefit from palliative treatments that control symptoms and extend survival while maintaining dignity and comfort.

Quick Summary Box

• Liver cancer curability depends heavily on early detection

• Stages I-II offering cure rates up to 70% through surgery or transplant

• Prevention through hepatitis vaccination and healthy lifestyle choices remains the most effective strategy

• New treatments continue improving outcomes even for advanced cases

• Regular screening for high-risk individuals and prompt medical attention for symptoms significantly impact survival chances

Related Resources

What Cancers Cause Elevated Liver Enzymes?

SGPT in Liver Function Tests: What You Need to Know

References

References

American Cancer Society. (2024a). Cancer Staging. Www.cancer.org. https://www.cancer.org/cancer/diagnosis-staging/staging.html 

American Cancer Society. (2024b, January 17). Key Statistics About Liver Cancer. Www.cancer.org. https://www.cancer.org/cancer/types/liver-cancer/about/what-is-key-statistics.html 

Asafo-Agyei, K. O., & Samant, H. (2023). Hepatocellular carcinoma. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK559177/ 

Bengtsson, B., Widman, L., Renumathy Dhanasekaran, Per Stål, Björkström, N. K., & Hannes Hagström. (2022). The risk of hepatocellular carcinoma in cirrhosis differs by etiology, age and sex: A Swedish nationwide population‐based cohort study. United European Gastroenterology, 10(5), 465–476. https://doi.org/10.1002/ueg2.12238 

Cao, M., Fan, J., Lu, L., Fan, C., Wang, Y., Chen, T., Zhang, S., Yu, Y., Xia, C., Lu, J., Chen, K., Yao, H., Chen, W., & Qu, C. (2022). Long term outcome of prevention of liver cancer by hepatitis B vaccine: Results from an RCT with 37 years. Cancer Letters, 536, 215652. https://doi.org/10.1016/j.canlet.2022.215652 

Chadha, S., Mukherjee, S., & Sanyal, S. (2025). Advancements and implications of artificial intelligence for early detection, diagnosis and tailored treatment of cancer. Seminars in Oncology, 52(3), 152349. https://doi.org/10.1016/j.seminoncol.2025.152349 

Jorgensen, C., Carnes, C. A., & Downs, A. (2016). “Know More Hepatitis:” CDC’s National Education Campaign to Increase Hepatitis C Testing among People Born between 1945 and 1965. Public Health Reports, 131(2_suppl), 29–34. https://doi.org/10.1177/00333549161310s205 

Lee, J.-G., Chang Moo Kang, Joon Seong Park, Kyung Sik Kim, Dong Sup Yoon, Jin Sub Choi, Woo Jung Lee, & Kyung Sik Kim. (2006). The Actual Five-year Survival Rate of Hepatocellular Carcinoma Patients after Curative Resection. 47(1), 105–105. https://doi.org/10.3349/ymj.2006.47.1.105 

Li, H., Liu, R., Li, J., Li, J., Wu, H., Wang, G., & Li, D. (2022). Tumor location influences perioperative and oncologic outcomes in solitary intrahepatic cholangiocarcinoma following curative resection: a multi-center analysis. HPB, 24(9), 1543–1550. https://doi.org/10.1016/j.hpb.2022.03.011 

Liver Cancer Survival Rates | Cancer of the Liver Survival Rates. (n.d.). Www.cancer.org. https://www.cancer.org/cancer/types/liver-cancer/detection-diagnosis-staging/survival-rates.html 

Milan Criteria - an overview | ScienceDirect Topics. (n.d.). Www.sciencedirect.com. https://www.sciencedirect.com/topics/medicine-and-dentistry/milan-criteria 

National Cancer Institute. (2022, May 19). Liver Cancer Diagnosis - NCI. Www.cancer.gov. https://www.cancer.gov/types/liver/what-is-liver-cancer/diagnosis 

Orcutt, S. T., & Anaya, D. A. (2018). Liver Resection and Surgical Strategies for Management of Primary Liver Cancer. Cancer Control : Journal of the Moffitt Cancer Center, 25(1). https://doi.org/10.1177/1073274817744621 

Palaniyandi Muthukutty, Hyun Young Woo, Murali Ragothaman, & So Young Yoo. (2023). Recent Advances in Cancer Immunotherapy Delivery Modalities. Pharmaceutics, 15(2), 504–504. https://doi.org/10.3390/pharmaceutics15020504 

Prevention» Hepatitis B Foundation. (n.d.). Www.hepb.org. https://www.hepb.org/research-and-programs/liver/prevention-of-liver-cancer/ 

R, R., M, M. A., V, M., SD, M., & K, M. (2024). NEXT GENERATION LIVER CANCER DETECTION: AN INTEGRATED APPROACH COMBINING ADVANCED IMAGING AND MACHINE LEARNING CLASSIFICATION. International Journal of Technical Research & Science, 9(Spl), 27–35. https://doi.org/10.30780/specialissue-iset-2024/039 

Reddy, K. R., McLerran, D., Marsh, T., Parikh, N., Roberts, L. R., Schwartz, M., Nguyen, M. H., Befeler, A., Page-Lester, S., Tang, R., Srivastava, S., Rinaudo, J. A., Feng, Z., & Marrero, J. A. (2023). Incidence and Risk Factors for Hepatocellular Carcinoma in Cirrhosis: The Multicenter Hepatocellular Carcinoma Early Detection Strategy (HEDS) Study. Gastroenterology, 165(4), 1053-1063.e6. https://doi.org/10.1053/j.gastro.2023.06.027 

Shiels, M. S., Engels, E. A., Yanik, E. L., McGlynn, K. A., Pfeiffer, R. M., & O’Brien, T. R. (2019). Incidence of hepatocellular carcinoma among older Americans attributable to hepatitis C and hepatitis B: 2001 through 2013. Cancer, 125(15), 2621–2630. https://doi.org/10.1002/cncr.32129 

Soresi, M., Terranova, A., Licata, A., Serruto, A., Montalto, G., Brancatelli, G., & Giannitrapani, L. (2017). Surveillance Program for Diagnosis of HCC in Liver Cirrhosis: Role of Ultrasound Echo Patterns. BioMed Research International, 2017, 1–8. https://doi.org/10.1155/2017/4932759 

Wang, W., & Wei, C. (2020). Advances in the early diagnosis of hepatocellular carcinoma. Genes & Diseases, 7(3). https://doi.org/10.1016/j.gendis.2020.01.014 

Wiener, R. S., Schwartz, L. M., Woloshin, S., & Welch, H. G. (2011). Population-based risk of complications following transthoracic needle lung biopsy of a pulmonary nodule. Annals of Internal Medicine, 155(3), 137. https://doi.org/10.1059/0003-4819-155-3-201108020-00003 

World. (2020, March 11). Hepatitis. Who.int; World Health Organization: WHO. https://www.who.int/health-topics/hepatitis#tab=tab_3:~:text=cure%20more%20than%2095%25%20of%20persons%20with%20HCV%20infection 

Yang, J. D. (2019). Detect or not to detect very early stage hepatocellular carcinoma? The western perspective. Clinical and Molecular Hepatology, 25(4), 335–343. https://doi.org/10.3350/cmh.2019.0010 

Yang, J.-Q., Wang, X.-G., & Wu, B. (2023). Incidence trend and prognosis of intrahepatic cholangiocarcinoma: a study based on the SEER database. Translational Cancer Research, 12(11), 3007–3015. https://doi.org/10.21037/tcr-23-1278 

Zheng, S., Xie, Q., & Cheng, J. (2018). Salvage liver transplant for hepatocellular carcinoma: rescues and benefits. Translational Gastroenterology and Hepatology, 3, 65–65. https://doi.org/10.21037/tgh.2018.09.06 

 

Frequently Asked Questions

Q: Can liver cancer be prevented?

A: Many liver cancers are preventable through hepatitis B vaccination, hepatitis C treatment, limiting alcohol consumption, maintaining healthy weight, and managing diabetes. The CDC estimates that vaccination and lifestyle changes could prevent up to 70% of liver cancer cases.

Q: What are the costs of liver cancer treatment in the US?

A: Treatment costs vary widely from $50,000 for ablation procedures to over $500,000 for liver transplantation, not including follow-up care. Most insurance plans cover medically necessary treatments, but patients should verify coverage and understand their out-of-pocket responsibilities before starting treatment.

Q: Are there new advancements in liver cancer treatment?

A: Recent breakthroughs include immunotherapy drugs like nivolumab and pembrolizumab, targeted therapies such as sorafenib and lenvatinib, and AI-assisted surgical planning. Clinical trials are testing combination treatments and personalized medicine approaches based on tumor genetics.